Here's the link. Conclusions:
- “A 5-day course of IVM did not improve time to resolution of symptoms in patients with mild COVID-19.”
- “A 5-day course of IVM in hospitalized patients with severe COVID-19 did not result in clinical improvement at the end of treatment, and no reduction in mortality was observed.”
- “Use of IVM did not reduce risk of oxygen requirement, ICU admission, invasive mechanical ventilation, or death in hospitalized patients with severe COVID-19.”
- “IVM showed no effect on symptom resolution in patients with mild COVID-19.”
- “Compared to SOC, use of IVM did not lead to faster recovery from mild to moderate COVID-19.”
- “Patients who received IVM showed no difference in viral clearance compared to those who received placebo.”
- “In hospitalized patients with COVID-19 pneumonia who were not critically ill, neither IVM nor HCQ decreased the number of in-hospital days, rate of respiratory deterioration, or mortality.”
A few small studies did indicate some positive results:
- A study that supposedly demonstrated that ivermectin combined with doxycycline was a superior treatment to hydroxychloroquine and azithromycin, but the actual results showed no statistical difference or evidence that either treatment was an improvement over standard of care.
- A very small study showed some evidence that the level of virus was reduced when ivermectin was given at three times the normal dose.
- Another very small study indicate that ivermectin shortened hospital stays, but didn’t have a placebo group or consider comorbidities
- Another very small study indicated that a handful of patients had reduced hospital stays, but the number being treated was so small it easily could have been a statistical fluke.
- The best of the studies showing some durable positive result involved about 250 patients, with a lowering of both hospital stays and mortality after a single dose of ivermectin.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.